Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022010322 - PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS

Publication Number WO/2022/010322
Publication Date 13.01.2022
International Application No. PCT/KR2021/008830
International Filing Date 09.07.2021
IPC
A61K 31/343 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
343condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • (주)나디안바이오 NADIANBIO LTD. [KR]/[KR]
Inventors
  • 소홍섭 SO, Hong Seob
  • 곽태환 KWAK, Tae Hwan
  • 김형진 KIM, Hyung Jin
Agents
  • 류종우 RYU, Jong Woo
  • 이내영 LEE, Rae Young
  • 한윤호 HAN, Yun Ho
Priority Data
10-2020-008571110.07.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS
(FR) COMPOSITION PHARMACEUTIQUE POUR LA PRÉVENTION OU LE TRAITEMENT DU CANCER, COMPRENANT UN COMPOSÉ À BASE DE NAPHTOQUINONE ET UN INHIBITEUR DE POINT DE CONTRÔLE IMMUNITAIRE EN TANT QUE PRINCIPES ACTIFS
(KO) 나프토퀴논계 화합물 및 면역관문 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
Abstract
(EN) The present invention provides a pharmaceutical composition for preventing or treating cancer, comprising: a naphthoquinone-based compound; and at least one selected from an immune checkpoint inhibitor and an immunogenic apoptosis inducer, as active ingredients, and exhibiting a significantly higher anticancer effect than in a case where each medication is administered alone. Accordingly, a synergistic anticancer effect of inhibiting the growth and metastasis of cancer cells can be expected in cancer cells in which anticancer effects were insignificant when conventional anticancer drugs were administered alone. Therefore, the composition comprising the naphthoquinone-based compound can be usefully used as a drug for preventing or treating cancer together with the immune checkpoint inhibitor and/or the immunogenic apoptosis inducer.
(FR) La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement du cancer, comprenant : un composé à base de naphtoquinone ; et au moins un médicament choisi parmi un inhibiteur de point de contrôle immunitaire et un inducteur d'apoptose immunogène, en tant que principes actifs, et présentant un effet anticancéreux significativement plus élevé que dans le cas où chaque médicament est administré seul. En conséquence, un effet anticancéreux synergique d'inhibition de la croissance et de la métastase de cellules cancéreuses peut être attendu dans des cellules cancéreuses dans lesquelles les effets anticancéreux étaient insignifiants lorsque les médicaments anticancéreux classiques ont été administrés seuls. Par conséquent, la composition comprenant le composé à base de naphtoquinone peut être utilisée utilement en tant que médicament pour prévenir ou traiter le cancer conjointement avec l'inhibiteur de point de contrôle immunitaire et/ou l'inducteur d'apoptose immunogène.
(KO) 본 발명은 나프토퀴논계 화합물; 및 면역관문 억제제 및 면역원성 세포사멸 유도제 중에서 선택되는 적어도 하나를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물로서, 각각의 제제를 단독으로 투여하는 경우 대비 현저히 높은 항암 효과를 나타낸다. 이에 따라 기존 항암제의 단독 투여로는 항암 효과가 미미하였던 암세포에서의 성장을 억제하고 암 세포의 전이를 억제하는 항암 시너지 효과를 기대할 수 있다. 따라서, 나프토퀴논계 화합물을 포함하는 조성물은 면역관문 억제제 및/또는 면역원성 세포사멸 유도제와 함께 암의 예방 또는 치료용 약물로서 유용하게 사용될 수 있다.
Latest bibliographic data on file with the International Bureau